Melanoma vaccines: What we know so far

ONCOLOGY

Volumn 19, Issue 1, 2005, Pages 97-108

  Bystryn, Jean Claude ^a   Reynolds, Sandra R ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2B INTERFERON; BCG VACCINE; CANCER VACCINE; CANVAXIN; DENDRITIC CELL VACCINE; DINITROPHENYLHAPTEN; FREUND ADJUVANT; GAMMA1B INTERFERON; GANGLIOSIDE GD2; GANGLIOSIDE GD3; GANGLIOSIDE GM2; GLYCOPROTEIN GP 100; HEAT SHOCK PROTEIN; INTERLEUKIN 2; INTERLEUKIN 4; KEYHOLE LIMPET HEMOCYANIN; MELACINE; MELAN A; MELANOMA ANTIGEN 1; MELANOMA ANTIGEN 3; MELANOMA VACCINE; MONOPHENOL MONOOXYGENASE; NY ESO 1 ANTIGEN; PHOSPHORYL LIPID A; PLACEBO; QS 21; RECOMBINANT ALPHA2B INTERFERON; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; RECOMBINANT INTERLEUKIN 2; UNINDEXED DRUG; VACCINIA ONCOLYSATE; MELANOMA SPECIFIC ANTIGENS; MELANOMA-SPECIFIC ANTIGENS; TUMOR MARKER; TUMOR PROTEIN;

ADJUVANT THERAPY; ANTIBODY RESPONSE; ANTIGEN PRESENTING CELL; CANCER IMMUNIZATION; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL DESTRUCTION; CELL KILLING; CHILL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DENDRITIC CELL; DRUG INDICATION; DRUG MEGADOSE; DRUG SAFETY; FEVER; HUMAN; IMMUNE RESPONSE; IMMUNOREACTIVITY; INFECTION; INJECTION SITE INDURATION; INJECTION SITE PAIN; INJECTION SITE REACTION; INJECTION SITE SWELLING; INJECTION SITE ULCER; LYMPHOCYTIC INFILTRATION; MELANOCYTE; MELANOMA; MELANOMA B16; MELANOMA CELL; NONHUMAN; OVERALL SURVIVAL; PHENOTYPE; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; REVIEW; T LYMPHOCYTE; TUMOR GROWTH; TUMOR IMMUNITY; TUMOR REGRESSION; UNSPECIFIED SIDE EFFECT; UVEITIS; VITILIGO; ANTIBODY PRODUCTION; DISEASE FREE SURVIVAL; IMMUNOLOGY; SKIN TUMOR;

ANTIBODY FORMATION; CANCER VACCINES; CLINICAL TRIALS; DISEASE-FREE SURVIVAL; HUMANS; MELANOMA; NEOPLASM PROTEINS; SKIN NEOPLASMS; T-LYMPHOCYTES; TUMOR MARKERS, BIOLOGICAL;

EID: 17844376252     PISSN: 08909091     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (65)

1. Bystryn JC, Shapiro RL, Oratz R: Cancer vaccines: Clinical applications: Partially purified tumor antigen vaccines, in DeVita V, Hellman S, Rosenberg SA (eds): Biologic Therapy of Cancer, 2nd ed, pp 668-679. Philadelphia, JB Lippincott, 1995.
2. Gromet MA, Epstein WL, Blois MS: The regressing thin melanoma. A distinctive lesson with metastatic potential. Cancer 42:2282-2292, 1978.
3. Balso M, Schiavon M, Cicogna PA, et al: Spontaneous regression of subcutaneous metastasis of cutaneous melanoma. Plast Reconstr Surg 90:1073-1076, 1992.
4. Kopf AW: Host defense against melanoma. Hosp Pract 6:116, 1971.
5. Bystryn J-C: Antibody response and tumor growth in syngeneic mice immunized to partially purified B16 melanoma associated antigens. J Immunol 120:96-101, 1978.
6. Oratz R, Cockerall C, Speyer JL, et al: Induction of tumor-infiltrating lymphocytes in human malignant melanoma metastases by immunization to melanoma antigen vaccine. J Biol Response Mod 8:355-358, 1989.
7. Hsueh EC, Gupta RK, Qi K, et al: Correlation of specific immune responses with survival in melanoma patients with distant metastases receiving polyvalent melanoma cell vaccine. J Clin Oncol 16:2913-2920, 1998.
8. Livingston PO, Wong GY, Adluri S, et al: Improved survival in stage III melanoma patients with GM2 antibodies: A randomized trial of adjuvant vaccination with GM2 ganglioside. J Clin Oncol 12:1036-1044, 1994.
9. Miller K, Abeless G, Oratz R, et al: Improved survival of patients with melanoma with an antibody response to immunization to a polyvalent melanoma vaccine. Cancer 75:495-502, 1995.
10. Reynolds SR, Zeleniuch-Jacquotte A, Shapiro RL, et al: Vaccine-induced CD8+ T cell responses to MAGE-3 correlate with clinical outcome in patients with melanoma. Clin Cancer Res 9:657-662, 2003.
11. Jäger E, Gnjatic S, Nagata Y, et al: Induction of primary NY-ESO-1 immunity: CD8+ T lymphocyte and antibody responses in peptide-vaccinated patients with NY-ESO-1+ cancers. Proc Natl Acad Sci 97:12198-12203, 2000.
12. Albino AP, Lloyd KO, Houghton AN, et al: Heterogeneity in surface antigen and glycoprotein expression of cell lines derived from different melanoma metastases of the same patient. J Exp Med 154:1764-1778, 1981.
13. Bystryn JC, Bernstein P, Liu P, et al: Immunophenotype of human melanoma cells in different metastases. Cancer Res 45:1772-1777, 1985.
14. Yeh MY, Hellstrom I, Hellstrom KE: Clonal variation in expression of a human melanoma antigen defined by monoclonal antibody. J Immunol 126:1312-1317, 1981.
15. Kageshita T, Hirai S, Ono T, et al: Downregulation of HLA class I antigen-processing molecules in malignant melanoma: Association with disease progression. Am J Pathol 154:745-754, 1999.
16. Reynolds SR, Celis E, Sette A, et al: HLA-independent heterogeneity of CD8+ T cell responses to MAGE-3, Melan A/MART-1, gp100, tyrosinase, MClR, and TRP-2 in vaccine-treated melanoma patients. J Immunol 161:6970-6976, 1998.
17. Miller K, Abeles G, Oratz R, et al: Improved survival of melanoma patients with an antibody response to immunization to a polyvalent melanoma vaccine. Cancer 75:495-502, 1995.
18. Hsueh EC, Essner R, Foshag LJ, et al: Prolonged survival after complete resection of disseminated melanoma and active immunotherapy with a therapeutic cancer vaccine. J Clin Oncol 20:4549-4554, 2002.
19. Sosman JA, Unger JM, Liu PY, et al: Adjuvant immunotherapy of resected, intermediate-thickness, node-negative melanoma with an allogeneic tumor vaccine: Impact of HLA class I antigen expression on outcome. J Clin Oncol 20:2067-2075, 2002.
20. Berd D: M-Vax: An autologous, hapten-modified vaccine for human cancer. Expert Opin Biol Ther 2:335-342, 2002.
21. Wallack MK, Sivanandham M, Balch CM, et al: Surgical adjuvant active specific immunotherapy for patients with stage III melanoma: The final analysis of data from a phase III, randomized, double-blind, multicenter vaccinia melanoma oncolysate trial. J Am Coll Surg 187:69-79, 1998.
22. Hersey P, Coates AS, McCarthy WH, et al: Adjuvant immunotherapy of patients with high-risk melanoma using vaccinia viral lysates of melanoma: Results of a randomized trial. J Clin Oncol 20:4181-4190, 2002.
23. Belli F, Arienti F, Sule-Soso J, et al: Active immunization of metastatic melanoma patients with interleukin-2 transduced allogeneic melanoma cells: Evaluation of efficacy and tolerability. Cancer Immunol Immunother 44:197-203, 1997.
24. Abdel-Wahab Z, Weltz C, Hester D, et al: A phase I clinical trial of immunotherapy with interferon-gamma gene-modified autologous melanoma cells: Monitoring the humoral immune response. Cancer 80:401-412, 1997.
25. Soiffer R, Lynch T, Mihm M, et al: Vaccination with irradiated autologous melanoma cells engineered to secrete human granulocyte-macrophage colony stimulating factor generates potent anti-tumor immunity in patients with metastatic melanoma. Proc Natl Acad Sci USA 95:13141-13146, 1998.
26. Moller P, Sun Y, Dorbic T, et al: Vaccine with IL-7 gene-modified autologous melanoma cells can enhance the anti-melanoma lytic activity in peripheral blood of patients with a good clinical performance status: A clinical phase I study. Br J Cancer 77:1907-1916, 1998.
27. Arienti F, Belli F, Napolitano F, et al: Vaccination of melanoma patients with interleukin 4 gene-transduced allogeneic melanoma cells. Hum Gene Ther 10:2907-2916, 1999.
28. Marincola FM, Jaffee EM, Hicklin DJ, et al: Escape of human solid tumors from T cell recognition: Molecular mechanisms and functional significance. Adv Immunol 74:181-273, 2000.
29. Weber J, Sondak VK, Scotland R, et al: Granulocyte-macrophage-colony- stimulating factor added to a multipeptide vaccine for resected stage II melanoma. Cancer 97:186-200, 2003.
30. Slingluff CL Jr, Yamshchikov G, Neese P, et al: Phase I trial of a melanoma vaccine with gpl00(280-288) peptide and tetanus helper peptide in adjuvant: Immunologic and clinical outcomes. Clin Can Res 7:3012-3024, 2001.
31. Banchereau J, Palucka AK, Dhodapkar M, et al: Immune and clinical response in patients with metastatic melanoma to CD34+ progenitor derived dendritic cell vaccine. Cancer Res 61:6451-6458, 2001.
32. Lau R, Wang F, Jeffery G, et al: Phase I trial of intravenous peptide-pulsed dendritic cells in patients with metastatic melanoma. J Immunother 24:66-78, 2001.
33. Kirkwood JM, Ibrahim JG, Sosman JA, et al: High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: Results of intergroup trial E1694/S9512/C509801. J Clin Oncol 19:2370-2380, 2001.
34. McCaffery M, Yao TJ, Williams L, et al: Immunization of melanoma patients with BEC2 anti-idiotypic monoclonal antibody that mimics GD3 ganglioside: Enhanced immunogenicity when combined with adjuvant. Clin Cancer Res 2:679-686, 1996.
35. Foon KA, Lutzky K, Baral RN, et al: Clinical and immune responses in advanced melanoma patients immunized with an anti-idiotype antibody mimicking disialoganglioside GD2. J Clin Oncol 18:376-384, 2000.
36. Van den Eynde BJ, Boon T: Tumor antigens recognized by T lymphocytes. Int J Clin Lab Res 27:81-86, 1997.
37. Parkhurst MR, Salgaller ML, Southwood S, et al: Improved induction of melanoma-reactive CTL with peptides from melanoma antigen gp100 modified at HLA-A*0201-binding residues. J Immunol 157:2539-2548, 1996.
38. Smith JW 2nd, Walker EB, Fox BA, et al: Adjuvant immunization of HLA-A2 positive melanoma patients with a modified gp100 peptide induces peptide-specific CD8+ T-cell responses. J Clin Oncol 21:1562-1573, 2003.
39. Ferrone S: Human tumor-associated antigen mimicry by anti-idiotypic antibodies. Ann N Y Acad Sci 690:214-224, 1993.
40. Bystryn JC, Zeleniuch-Jacquotte A, Oratz R, et al: Double-blind trial of a polyvalent, shed-antigen, melanoma vaccine. Clin Cancer Res 7:1882-1887, 2001.
41. Applebaum J, Reynolds S, Knispel J, et al: Identification of melanoma antigens that are immunogenic in humans and expressed in vivo. J Natl Cancer Inst 90:146-149, 1998.
42. Blachere NE, Srivastava PK: Heat shock protein based cancer vaccines and related thoughts on immunogenicity of human tumors. Semin Cancer Biol 6:349-355, 1995.
43. Belli F, Testori A, Rivoltini L, et al: Vaccination of metastatic melanoma patients with autologous tumor-derived heat shock protein gp96-peptide complexes: Clinical and immunologic findings. J Clin Oncol 20:4169-4180, 2002.
44. Relyveld EH, Ben-Efraim S: Preparation of vaccines by the action of glutaldehyde on toxins, bacteria, viruses, allergens and cells. Methods Enzymol 93:24-60, 1983.
45. Chang AE, Redman BG, Whitfield JR, et al: A phase I trial of tumor lysate-pulsed dendritic cells in the treatment of advanced cancer. Clin Cancer Res 8:1021-1032, 2002.
46. Chapman PB, Morissey DM, Panageas KS, et al: Induction of antibodies against GM2 ganglioside by immunizing melanoma patients using GM2-keyhole limpet hemocyanin + QS21 vaccine: A dose-response study. Clin Cancer Res 6:874-879, 2000.
47. Rosenberg SA, Zhai Y, Yang JC, et al: Immunizing patients with metastatic melanoma using recombinant adenoviruses encoding MART-1 or gp100 melanoma antigens. J Natl Cancer Inst 90:1894-1900, 1998.
48. Steinman RM: Dendritic cells and the control of immunity: Enhancing the efficiency of antigen presentation. Mt Sinai J Med 68:106-166, 2001.
49. Nestle FO, Alijagic S, Gilliet M, et al: Vaccination of melanoma patients with peptide-or tumor lystae-pulsed dendritic cells. Nat Med 4:328-332, 1998.
50. Oratz R, Shapiro RL, Johnston D, et al: IL-2 liposomes markedly enhance the activity of a polyvalent melanoma vaccine (abstract 1356). Proc Am Soc Clin Oncol 15:436, 1996.
51. Kirkwood JM, Strawderman MH, Ernstoff MS, et al: Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: The Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol 14:7-17, 1996.
52. Keilholz U, Weber J, Finke JH, et al: Immunologie monitoring of cancer vaccine therapy: Results of a workshop sponsored by the Society for Biological Therapy. J Immunother 25:97-138, 2002.
53. Cui J, Chen D, Oratz R, et al: Induction of cytolytic antibodies to melanoma by immunization to a polyvalent melanoma antigen vaccine. Vaccine Res 3:175-182, 1994.
54. Reynolds SR, Oratz R, Shapiro RL, et al: Stimulation of CD8+ T cell responses to MAGE-3 and Melan A/MART-1 by immunization to a polyvalent melanoma vaccine. Int J Cancer 72:972-976, 1997.
55. Maraveyas A, Baban B, Kennard D, et al: Possible improved survival of patients with stage IV AJCC melanoma receiving SRL 172 immunotherapy: Correlation with induction of increased levels of intracellular interleukin-2 in peripheral blood lymphocytes. Ann Oncol 10:817-824, 1999.
56. Scheibenbogen C, Schmittel A, Keilholz U, et al: Phase 2 trial of vaccination with tyrosinase peptides and granulocyte-macrophage colony-stimulating factor in patients with metastatic melanoma. J Immunother 23:275-281, 2000.
57. Chung MH, Gupta RK, Hsueh E, et al: Humoral immune response to a therapeutic polyvalent cancer vaccine after complete resection of thick primary melanoma and sentinel lymphadenectomy. J Clin Oncol 21:313-319, 2003.
58. Reynolds SR, Albrecht J, Shapiro RL, et al: Changes in the presence of multiple markers of circulating melanoma cells correlates with clinical outcome in patients with melanoma. Clin Cancer Res 9:1497-1502, 2003.
59. Garbe C, Leiter U, Ellwanger U, et al: Diagnostic value and prognostic significance of protein S-100, melanoma-inhibitory activity, and tyrosinase/MART-1 reverse transcription-polymerase chain reaction in the follow-up of high-risk melanoma patients. Cancer 97:1737-1745, 2003.
60. Bystryn J-C, Laky D, Shapiro RL, et al: Prolonged survival of vaccine-treated patients with resected stage IV melanoma (abstract 2911). Proc Am Soc Clin Oncol 22:724, 2003.
61. Bystryn J-C, Oratz R, Roses D, et al: Relationship between immune response to melanoma vaccine immunization and clinical outcome in stage II malignant melanoma. Cancer 69:1157-1164, 1992.
62. Mitchell MS, Rechtman DJ, Von Eschen KB: A randomized phase III trial of Melacine versus combination chemotherapy in patients with disseminated melanoma. Can J Infect Dis 6(suppl C):347C, 1995.
63. Nestle FO, Kerl H: Neoplasms of the skin, in Bolognia JL, Jorizzo JL, Rapini R, et al (eds): Dermatology, p 1789. London, Mosby, 2003.
64. Roberts DL, Anstey AV, Barlow RJ, et al: U.K. guidelines for the management of cutaneous melanoma. Br J Dermatol 146:7-17, 2002.
65. 2 is superior to whole cells. J Immunol 138:1524-1529, 1987.